Gamma knife radiosurgery for growth hormone-producing adenomas

J Clin Neurosci. 2010 Mar;17(3):299-304. doi: 10.1016/j.jocn.2009.05.040. Epub 2010 Jan 13.

Abstract

We evaluated the endocrinological outcomes of gamma knife radiosurgery (GKS) for the treatment of growth hormone (GH)-producing pituitary adenomas. Twenty-six patients treated with GKS (median treatment [tumour] volume: 0.8 mL; median marginal radiation dose: 20Gy) were followed for a median of 84 months. "Disease remission" was defined as either nadir levels of GH <1 microg/L during an oral glucose load, or random GH levels <2 microg/L and normal age-adjusted and sex-adjusted levels of insulin-like growth factor without pituitary suppressive medications. The remission rate was 38% (10/26) and the 5-year and 10-year actuarial remission rates were 16.9% and 47.4%, respectively. Two patients (8%) suffered hypopituitarism requiring medication, but no other serious deficits were observed. Although GKS requires a relatively long time to achieve hormonal remission, it is a very useful, long-term treatment for GH-producing adenomas. We propose that compared to continuing life-long medication, GKS is less invasive and more cost effective.

Publication types

  • Evaluation Study

MeSH terms

  • Adenoma / metabolism*
  • Adenoma / surgery*
  • Adolescent
  • Adult
  • Antineoplastic Agents, Hormonal / therapeutic use
  • Case-Control Studies
  • Chi-Square Distribution
  • Child
  • Female
  • Human Growth Hormone / metabolism*
  • Humans
  • Longitudinal Studies
  • Magnetic Resonance Imaging / methods
  • Male
  • Middle Aged
  • Octreotide / therapeutic use
  • Pituitary Neoplasms / metabolism*
  • Pituitary Neoplasms / surgery*
  • Radiosurgery / methods*
  • Retrospective Studies
  • Young Adult

Substances

  • Antineoplastic Agents, Hormonal
  • Human Growth Hormone
  • Octreotide